A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis

Exclusion Criteria

• •1. A primary diagnosis of chronic obstructive pulmonary disease (COPD) or asthma as judged by the Investigator.
• •2. Bronchiectasis due to cystic fibrosis.
• •3. Current smokers as defined per Centers for Disease Control (CDC).
• •4. Known or suspected immunodeficiency disorder, including history of invasive opportunistic infections.
• •5. Known history of human immunodeficiency virus (HIV) infection.
• •6. Currently being treated for nontuberculous mycobacteria (NTM) lung infection, allergic bronchopulmonary aspergillosis, or tuberculosis (TB).
• •7. Active and current symptomatic infection by 2019 corona virus disease (COVID-19).
• •8. Inability to follow the procedures of the study (eg, due to language problems or psychological disorders).
• •9. Receiving medications or therapy that are prohibited as concomitant medications.
• •10. Previously participated in a clinical trial for brensocatib.
• •11. Received any live attenuated vaccine within 4 weeks prior to the first administration of brensocatib.
• •12. Suffering an exacerbation 4 weeks before Screening or during the Screening period.
• •13. Adult participants only: Have compliance issues with completion of electronic diary entries during the Screening Period and in the opinion of the Investigator, compliance is unlikely to improve during the study.
• •14. Participated in any other interventional clinical studies within 3 months before Screening Visit.
• •15. History of alcohol or drug abuse within 6 months prior to the Screening Visit.
• •16. Is the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the study.
• •17. Known history of hypersensitivity to brensocatib or any of its excipients.